Zeteo Biomedical said that the company will supply its ZEOx2 nasal delivery system and unit dose packaging for use with a shelf-stable SARS-CoV-2 vaccine in development at the Nanovaccine Institute at Iowa State University. Zeteo is already working with Iowa State on an intranasal universal flu vaccine. The ZEOx2 platform can be used for intranasal delivery of dry powders, or it can be used to reconstitute a dry powder and deliver it as a liquid.
Iowa State University professor Balaji Narasimhan, Director of the Nanovaccine Institute, said, “Our approach leverages the strengths of ISU’s nanovaccine platform and Zeteo’s ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up.”
Zeteo Biomedical President Timothy Sullivan commented, “We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19.”
Sullivan is also President and CEO of Mystic Pharmaceuticals, which has patents covering a dry powder/reconstituted powder delivery platform and which shares an address with Zeteo.
Read the Zeteo Biomedical press release.
